Tomas Navratil serves as the Chief Development Officer at Glaukos Corporation, a leading ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. In his role, Navratil is responsible for overseeing the company's research and development efforts, ensuring the successful advancement of innovative products from concept to market. His strategic leadership and vision have been instrumental in driving Glaukos' growth and expanding its product portfolio. Prior to joining Glaukos, Navratil held various leadership positions in the pharmaceutical and medical device industries, amassing a wealth of experience in product development, clinical research, and regulatory affairs. He has a proven track record of successfully navigating the complex landscape of drug and device development, bringing multiple products from early-stage research to regulatory approval and commercialization. Navratil's expertise in ophthalmology, coupled with his strong business acumen, has made him a valuable asset to Glaukos and a respected figure in the industry. Under Navratil's guidance, Glaukos has made significant strides in advancing its pipeline of novel therapies, including the development of micro-invasive glaucoma surgery (MIGS) devices and sustained-release drug delivery systems. His leadership has been pivotal in the company's efforts to address unmet medical needs and improve patient outcomes in the field of ophthalmology. Navratil's dedication to innovation and his commitment to the company's mission have solidified his reputation as a driving force behind Glaukos' success and growth.